EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Oral antidiabetic combination therapy with sulphonylureas and metformin



Oral antidiabetic combination therapy with sulphonylureas and metformin



Diabete & Metabolisme 17(1 Pt 2): 224-231



In a multicentre trial in general practice, a total of 1823 type 2 diabetics, not adequately controlled by diet and maximal sulphonylurea therapy, were treated with additional metformin 850--2 550 mg/d for 12 weeks. The average postprandial blood sugar decreased from 15.48 mmol/l to 10.43 mmol/l, HbA1 fell from 11.0% to 9.1%. Serum triglycerides decreased from an initial level of 2.87 mmol/l to 2.41 mmol/l an mean total cholesterol from 6.76 mmol/l to 6.16 mmol/l. In addition, body weight and blood pressure declined steadily. All the described changes were statistically significant. The metformin-sulphonylurea combination therapy was generally well tolerated. Gastrointestinal side effects occurred in about 7% of patients, but mainly in the first week of treatment, generally disappearing spontaneous as therapy was continued. Side effects led to a discontinuation of the treatment in 4.2% of patients.

(PDF 0-2 workdays service: $29.90)

Accession: 040874534

Download citation: RISBibTeXText

PMID: 1936481



Related references

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes, Obesity & Metabolism 16(10): 977-983, 2015

Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy. Clinical Therapeutics 33(9): 1281-1288, 2012

Benefits And Risks of Vildagliptin/Metformin Versus Sulphonylureas/Metformin Combination Therapy In Type 2 Diabetes Mellitus (T2dm) From Patient's Perspective: Real-World Data. Value in Health 18(7): A615-A615, 2015

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Current Medical Research and Opinion 25(3): 607-615, 2010

Clinical experiences in oral antidiabetic therapy with sulphonylureas and biguanides. Australian and New Zealand Journal of Medicine 1: Suppl 2:47-56, 1971

New class of oral antidiabetic drugs. Effective in combination with metformin. Mmw Fortschritte der Medizin 149(1-2): 17-17, 2007

Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clinical Therapeutics 24(3): 460-467, March, 2002

Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. Journal of Clinical Pharmacology 47(1): 48-55, 2006

Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Collegium Antropologicum 27(1): 181-187, 2003

Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. Journal of Diabetes and Its Complications 29(8): 1266-1271, 2016

The oral antidiabetic agents. The mode of action of sulphonylureas. Anglo-German Medical Review. Deutsch-Englische Medizinische Rundschau 1: 310-333, 1962

Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated. Prescrire International 14(78): 133-139, 2005

Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: Influence of prior antidiabetic drug regimen. Journal of Diabetes & its Complications 17(4): 211-217, July-August, 2003